1. Home
  2. BBY vs INSM Comparison

BBY vs INSM Comparison

Compare BBY & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BBY
  • INSM
  • Stock Information
  • Founded
  • BBY 1966
  • INSM 1988
  • Country
  • BBY United States
  • INSM United States
  • Employees
  • BBY N/A
  • INSM N/A
  • Industry
  • BBY Consumer Electronics/Video Chains
  • INSM Biotechnology: Pharmaceutical Preparations
  • Sector
  • BBY Consumer Discretionary
  • INSM Health Care
  • Exchange
  • BBY Nasdaq
  • INSM Nasdaq
  • Market Cap
  • BBY 16.0B
  • INSM 14.3B
  • IPO Year
  • BBY N/A
  • INSM 2000
  • Fundamental
  • Price
  • BBY $72.34
  • INSM $77.99
  • Analyst Decision
  • BBY Buy
  • INSM Strong Buy
  • Analyst Count
  • BBY 19
  • INSM 16
  • Target Price
  • BBY $93.11
  • INSM $95.36
  • AVG Volume (30 Days)
  • BBY 4.1M
  • INSM 1.6M
  • Earning Date
  • BBY 03-04-2025
  • INSM 05-08-2025
  • Dividend Yield
  • BBY 5.25%
  • INSM N/A
  • EPS Growth
  • BBY N/A
  • INSM N/A
  • EPS
  • BBY 4.28
  • INSM N/A
  • Revenue
  • BBY $41,528,000,000.00
  • INSM $363,707,000.00
  • Revenue This Year
  • BBY $1.74
  • INSM $30.31
  • Revenue Next Year
  • BBY $2.71
  • INSM $118.39
  • P/E Ratio
  • BBY $16.93
  • INSM N/A
  • Revenue Growth
  • BBY N/A
  • INSM 19.17
  • 52 Week Low
  • BBY $69.29
  • INSM $21.92
  • 52 Week High
  • BBY $103.71
  • INSM $84.91
  • Technical
  • Relative Strength Index (RSI)
  • BBY 35.93
  • INSM 51.43
  • Support Level
  • BBY $73.99
  • INSM $76.05
  • Resistance Level
  • BBY $75.74
  • INSM $79.12
  • Average True Range (ATR)
  • BBY 2.10
  • INSM 2.52
  • MACD
  • BBY 0.29
  • INSM 0.11
  • Stochastic Oscillator
  • BBY 23.63
  • INSM 64.00

About BBY Best Buy Co. Inc.

With $43.5 billion in consolidated 2023 sales, Best Buy is the largest pure-play consumer electronics retailer in the US, boasting roughly 8.3% share of the North American market and north of 33% share of offline sales in the region, per our calculations, CTA, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the covid-19 pandemic, have seen the US e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.

About INSM Insmed Incorporated

Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.

Share on Social Networks: